Article
A large portion of meningococcal antigen typing system-negative meningococcal strains from spain is killed by sera from adolescents and infants immunized with 4CMenB.
Clinical and vaccine immunology : CVI - 1 Apr 2015
Abad R, Biolchi A, Moschioni M, Giuliani M M, Pizza M, Vázquez J A
Abstract excerpt
A new vaccine (the 4CMenB 4-component protein vaccine [Bexsero], which includes PorA, factor H-binding protein [fHbp], neisserial heparin-binding antigen [NHBA], and Neisseria adhesin A [NadA]) against serogroup B meningococci has recently been approved for use in people older than age 2 months in Europe, Australia, and Canada. Preapproval clinical efficacy studies are not feasible for invasive meningococcal...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.